Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients

Vaccine

Volumn 30, Issue 6, 2012, Pages 1108-1114

  Lertdumrongluk, Paungpaga ^a   Changsirikulchai, Siribha ^a   Limkunakul, Chutatip ^a   Prachukthum, Poonsuk ^a   Punpiput, Prapaipun ^a   Buppanharun, Rungtiva ^a   Chotpitayasunondh, Chuencheevit ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Hemodialysis; Immunogenicity; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SEROCONVERSION; SEROPROTECTION; TREATMENT OUTCOME; VIRUS IMMUNITY;

ADULT; AGED; ANTIBODIES, VIRAL; COHORT STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856314678     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.023     Document Type: Article

References (27)

1. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(June (25)):2605-2615.
2. Perez-Padilla R., de la Rosa-Zamboni D., Ponce de Leon S., Hernandez M., Quinones-Falconi F., Bautista E., et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009, 361(August (7)):680-689.
3. Marcelli D., Marelli C., Richards N. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant 2009, 24(December (12)):3566-3572.
4. Gilbertson D.T., Unruh M., McBean A.M., Kausz A.T., Snyder J.J., Collins A.J. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 2003, 63(February (2)):738-743.
5. Scharpe J., Peetermans W.E., Vanwalleghem J., Maes B., Bammens B., Claes K., et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009, 54(July (1)):77-85.
6. Song J.Y., Cheong H.J., Ha S.H., Kee S.Y., Jeong H.W., Kim W.J. Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol 2006, 26(2):206-211.
7. Antonen J.A., Hannula P.M., Pyhala R., Saha H.H., Ala-Houhala I.O., Pasternack A.I. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000, 86(September (1)):56-61.
8. Beyer W.E., Versluis D.J., Kramer P., Diderich P.P., Weimar W., Masurel N. Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components. Vaccine 1987, 5(March (1)):43-48.
9. Cavdar C., Sayan M., Sifil A., Artuk C., Yilmaz N., Bahar H., et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003, 37(1):71-76.
10. Vogtlander N.P., Brown A., Valentijn R.M., Rimmelzwaan G.F., Osterhaus A.D. Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine 2004, 22(June (17-18)):2199-2201.
11. Labriola L., Hombrouck A., Marechal C., Van Gucht S., Brochier B., Thomas I., et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant 2011, 26(April (4)):1424-1428.
12. Temiz G., Kasifoglu N., Kiris A., Ozturk S., Sahin G., Yalcin A.U., et al. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail 2010, 32(July (6)):716-720.
13. Wiesik-Szewczyk E., Romanowska M., Mielnik P., Chwalinska-Sadowska H., Brydak L.B., Olesinska M., et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010, 29(June (6)):605-613.
14. Lerdsamran H., Pittayawonganon C., Pooruk P., Mungaomklang A., Iamsirithaworn S., Thongcharoen P., et al. Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population. PloS One 2011, 6(1):e16164.
15. Rudenko L.G., Slepushkin A.N., Monto A.S., Kendal A.P., Grigorieva E.P., Burtseva E.P., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993, 168(October (4)):881-887.
16. Warburton M.F. Immunization against influenza. Med J Aust 1972, 1(March (11)):546-547.
17. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(December (25)):2414-2423.
18. Eleftheriadis T., Antoniadi G., Liakopoulos V., Kartsios C., Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20(September-October (5)):440-451.
19. Janus N., Vacher L.V., Karie S., Ledneva E., Deray G. Vaccination and chronic kidney disease. Nephrol Dial Transplant 2008, 23(March (3)):800-807.
20. Kamata K., Okubo M., Sada M. Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components. Clin Exp Immunol 1983, 54(October (1)):277-281.
21. Newberry W.M., Sanford J.P. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 1971, 50(June (6)):1262-1271.
22. Kovacic V., Sain M., Vukman V. Efficient haemodialysis improves the response to hepatitis B virus vaccination. Intervirology 2002, 45(3):172-176.
23. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
24. Song J.Y., Cheong H.J., Hwang I.S., Choi W.S., Jo Y.M., Park D.W., et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010, 28(May (23)):3929-3935.
25. Zuccotti G.V., Scaramuzza A., Riboni S., Mameli C., Pariani E., Tanzi E., et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009, 27(August (39)):5357-5362.
26. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006, 48(July (Suppl. 1)):S2-S90. National Kidney Foundation Center.
27. Dikow R., Eckerle I., Ksoll-Rudek D., Hampel H., Schwenger V., Zeier M., et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011, 57(May (5)):716-723.